Cary, N.C. , May 9, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Verastem Oncology as a limited specialty pharmacy provider for AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib capsules; defactinib tablets,) a combination treatment for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.
AVMAPKI FAKZYNJA CO-PACK, approved by the U.S. Food and Drug Administration (FDA) on May 8, 2025, is a novel combination of AVMAPKI (avutometinib capsules) and FAKZYNJA (defactinib tablets,) for adults with KRAS-mutated recurrent LGSOC who received prior systemic therapy.
LGSOC is a rare, highly recurrent, and fatal ovarian cancer that differs from high-grade serous ovarian cancer (HGSOC) in both its biology and behavior. LGSOC is characterized by its’ slow growth, yet persistent nature. It disproportionately affects younger women and exhibits less sensitivity to chemotherapy, when compared to HGSOC.
“AVMAPKI FAKZYNJA CO-PACK is the first FDA-approved treatment for patients with this rare ovarian cancer,” says George Paschal, sr. director, business development, Biologics by McKesson. “Biologics is privileged to be selected by Verastem Oncology as a specialty pharmacy, supporting patients managing a diagnosis that is often challenging and serious.”
Biologics by McKesson is committed to and recognized for its level of customer service as well as its innovative, high-touch, and multidisciplinary approach. Putting patients first in all they do, the Biologics’ pharmacy team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients.
For the full prescribing information for AVMAPKI™ FAKZYNJA™ CO-PACK, please click here.